|
|
||||||||
J Thorac Cardiovasc Surg 2007;134:271
© 2007 The American Association for Thoracic Surgery
Letter to the Editor |
Centennial Medical Center, Vanderbilt University, Nashville, Tenn
| The first 20% of the full text of this article appears below. |
To the Editor:
The recent publication of a large randomized trial of amiodarone arrhythmia prophylaxis after cardiac surgery (PAPABEAR) is of great interest.1
It was striking how similar the results of this trial were to our previous observational analysis of perioperative amiodarone during mitral valve repair,2
and a detailed comparison raises several points. First, both studies concluded that amiodarone was effective, reducing postoperative atrial arrhythmias by half and virtually eliminating mortality from ventricular arrhythmias. Second, serious complications of a brief perioperative administration were rare. In PAPABEAR, bradycardia requiring dose reduction occurred in 5.7% of cases and was considered a side effect. In
This article has been cited by other articles:
![]() |
J. S. Rankin, O. Oguntolu, R. S. Binford, D. S. Trochtenberg, L. H. Muhlbaier, and C. W. Stratton Management of immune dysfunction after adult cardiac surgery J. Thorac. Cardiovasc. Surg., September 1, 2011; 142(3): 575 - 580. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |